Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586258 | 0.78 | — | — | |
| SCHEMBL16118724 | 0.74 | — | — | |
| SCHEMBL22369864 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19566928 | 0.73 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16450714 | 0.73 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21504185 | 0.72 | — | — | |
| SCHEMBL25518842 | 0.72 | — | — | |
| SCHEMBL17780269 | 0.69 | — | — | |
| SCHEMBL16118625 | 0.67 | — | — | |
| SCHEMBL21503987 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-9724316-B2 | Bicyclic analgesic compounds | KALYRA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160374968-A1 | BICYCLIC ANALGESIC COMPOUNDS | KTHERA, LLC | 2016-12-29 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374968-A1 | BICYCLIC ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | GRIN2D 1053/4885GRIN3B 541/4885GRIN1 571/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | GRIN2D 73/4885GRIN3B 52/4885GRIN1 91/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | GRIN2D 2655/4885GRIN3B 2641/4885GRIN1 3183/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | GRIN2D 2887/4885GRIN3B 2905/4885GRIN1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.